← All Briacell Therapeutics CORP filings

Briacell Therapeutics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BCTX
Briacell Therapeutics CORP
10-K: BriaCell Reports Increased Net Loss Amid Clinical Progress
BriaCell Therapeutics Corp. reported a significantly increased net loss for fiscal year 2025, primarily due to warrant revaluation, while advancing its lead immunotherapy candidates in breast and prostate cancer trials.
NASDAQ
BCTX
Briacell Therapeutics CORP
10-K: BriaCell Therapeutics Corp. Reports Full Year 2024 Results, Highlights Clinical Progress
BriaCell Therapeutics Corp. released its annual report for the fiscal year ended July 31, 2024, detailing financial results and clinical advancements in its immunotherapy programs.